What is Morgan's updated view on this red hot ASX healthcare stock?

This company released some exciting results.

It has been a red hot 2026 for ASX healthcare stock Vitrafy Life Sciences Ltd (ASX: VFY). 

Vitrafy researches and develops cryopreservation technology. The company offers cryopreservation devices, thawing devices, packaging, and software platform.

In 2026, it has risen an impressive 107%. 

This included a 13% jump last Friday after the company released an announcement to the ASX. 

a nurse wearing a medical mask prepares a patient for a blood donation in a surgical setting.

Image source: Getty Images

What did the company announce?

On Friday, the healthcare company announced the successful completion of the Phase II in-vitro study with United States Army Institute of Surgical Research (part of the Defense Health Agency) ("USAISR"). 

According to the release, excellent results were achieved using the Vitrafy cryopreservation ecosystem across all tested protocols when compared to existing regulatory and quality guidelines for platelet use.

Building upon the Phase I results, the Phase II USAISR in-vitro results highlight that all protocols tested via Vitrafy's cryopreservation ecosystem outperform the existing regulatory and quality guidelines currently set for the use of platelets

What does this all mean?

The company tested different ways of freezing and thawing platelets (blood components used to stop bleeding).

All methods passed the minimum medical standards needed for human use.

One method in particular – using 3% DMSO without needing a "wash" step – performed best.

Normally frozen platelets are difficult and expensive to prepare after thawing.

Vitrafy's "no-wash" process means hospitals, ambulances, military units, or remote clinics could potentially thaw and use platelets quickly without special lab equipment or trained technicians.

That could make it easier to store emergency blood supplies for disasters, trauma care, rural medicine, and battlefield injuries.

They achieved 94% platelet recovery after thawing, which means most platelets survived the freezing process and still functioned properly.

They also maintained strong clotting ability, which is critical in trauma situations.

Investors were seemingly pleased with these results, as the ASX healthcare stock rose 13% last Friday following the release. 

What is Morgan's take?

Following this announcement, the team at Morgans provided updated guidance on this ASX healthcare stock. 

It said Vitrafy has released final Phase II in-vitro platelet results from USAISR, with all three cryopreservation protocols exceeding fresh-platelet quality benchmarks. 

The headline result was 94% post-thaw recovery using the 3% DMSO no-wash protocol, well ahead of the FDA/AABB (~75%) and European (~50%) thresholds. The study is independently authored by the US Army across 20 donors and 60+ samples at commercial volumes, delivering on a core IPO commitment made at listing in November 2024. 

No FDA-approved no-wash frozen platelet product exists commercially in the US, positioning Vitrafy to address a genuine category gap. Shares trading up strongly from the $1.20 YTD lows, and +27% on the 2024 IPO price.

This ASX healthcare stock closed trading last week at $2.65. 

Current targets from brokers are hovering around the $3.00 mark. 

Motley Fool contributor Aaron Bell has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A woman looks nonplussed as she holds up a handful of Australian $50 notes.
Healthcare Shares

At $199, are CSL shares a bargain buy or a risky investment?

Here's my verdict on the ASX biotech stock.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

ASX 200 healthcare shares rebound 57% in 5 months. Here's 1 to buy and 1 to sell: experts

It's time to take profits on one share, while the other has more growth left, say these experts.

Read more »

Falling pills in a blue background.
Healthcare Shares

Mayne shares are up 80% on takeover news, but there's still money to be made

Major shareholders are backing the deal in.

Read more »

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

ResMed or Cochlear: Which ASX healthcare share would I buy today?

I like both businesses for the long term, but their recent financial performances have given me something to think about.

Read more »